Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $2.79 and last traded at $2.89, with a volume of 2591900 shares. The stock had previously closed at $2.89.

Several equities research analysts have weighed in on ACHN shares. Ladenburg Thalmann Financial Services cut their target price on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a research note on Tuesday, September 12th. Leerink Swann restated a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th. Robert W. Baird restated a “neutral” rating and set a $4.00 target price (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Finally, Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $5.13.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. During the same period in the prior year, the firm earned ($0.15) EPS. research analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current fiscal year.

In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.24% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in ACHN. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 800 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Achillion Pharmaceuticals by 18.6% in the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 4,144 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Achillion Pharmaceuticals by 53.8% in the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 15,000 shares during the last quarter. Voya Investment Management LLC lifted its stake in shares of Achillion Pharmaceuticals by 13.7% in the 2nd quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 6,730 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Achillion Pharmaceuticals by 6.4% in the 2nd quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 3,410 shares during the last quarter. Institutional investors own 76.93% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/achillion-pharmaceuticals-achn-reaches-new-12-month-low-at-2-79/1769168.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.